A practical guide to Japan’s regenerative medicine landscape

Stem Cell Hospitals in Japan

If you are comparing options in Japan, first identify which route your diagnosis actually fits: a PMDA-approved regenerative product, a registered clinical study, or a separate regenerative medicine provision plan. The evidence, eligibility, procedure, cost and follow-up can be very different.

Help Me Sort Through the OptionsWhatsApp I’ll Send What I HaveLINE

Case preparationOrganize diagnosis, timeline, imaging, laboratory results and current care.

Appointment supportPrepare the information needed for a Japan-side appointment request.

Medical translationSupport communication around records, questions, scheduling and written instructions.

Make sure you know which route you’re on

Approval, research and private provision are not the same thing

A patient can see the words “stem cells in Japan” used for very different legal and clinical pathways. Confirm the route before comparing outcomes or prices.

MHLW regenerative medicine provision process

PMDA-approved regenerative medical product

Approval applies to an exact product, indication and method of use. A product approved for spinal cord injury, Parkinson disease or ischemic cardiomyopathy does not create approval for unrelated diseases or a different cell preparation.

Clinical research route

Research protocols have defined eligibility, endpoints and follow-up. Under the Japanese framework, regenerative medicine conducted as research is submitted through jRCT. Being studied is not the same as being proven effective for routine care.

ASRM provision plan

Japan’s Act on the Safety of Regenerative Medicine uses risk classes and requires committee review and submission of a provision plan. A submitted plan is a separate route from PMDA marketing approval.

Current framework: the amended law took effect on May 31, 2025. MHLW states that providing regenerative medicine without the required provision-plan submission is a legal violation. Check the MHLW e-Regenerative Medicine portal.

What the Japanese review data actually tell us

What the Japanese data actually show

A percentage is only useful when you know the patient number, comparison group, outcome and follow-up time. The figures below come from PMDA review material and should not be read as your personal chance of improvement.

Clinical records used to compare published regenerative medicine evidence in Japan

Study results answer a narrow question about patients who met that study’s criteria. They do not automatically apply to a different disease stage, timing, cell source or administration method.

Traumatic spinal cord injury

Stemirac · autologous (patient’s own) bone-marrow MSCs · IV infusion

N=13 efficacy patients · no control · 220 days

Published result

12/13 improved by at least one AIS grade. 3/13 improved by at least two grades. Mean SCIM-III change was +27.2 points with a 95% CI of 7.6 to 46.7.

What it does not prove

The study was exploratory and uncontrolled. PMDA noted that spontaneous recovery and rehabilitation could affect the result. Treatment in the study was given in the acute-to-subacute period, not years after injury.

PMDA Stemirac review report

Parkinson disease

AMCHEPRY · allogeneic (donor-derived) iPS dopaminergic neural progenitor cells · stereotactic brain implantation

N=6 efficacy-evaluable · exploratory · 24 months

Published result

At 24 months, 4/6 patients met the review report’s meaningful-improvement threshold for the OFF-state MDS-UPDRS Part III motor score.

What it does not prove

The efficacy dataset was very small and had no routine-care comparator. PMDA required continued post-marketing confirmation. This is brain surgery using an iPS-derived neural product, not a general IV MSC treatment.

PMDA AMCHEPRY review report

Severe ischemic cardiomyopathy

RiHEART · allogeneic (donor-derived) iPS heart-muscle cell sheets · open-chest cardiac surgery

N=8 · open-label · no control · 52 weeks

Published result

At Week 52, 8/8 improved by at least one NYHA class, 4/8 improved six-minute walk distance by at least 45 m, and 4/8 improved peak VO2 by at least 10%.

What it does not prove

The study was too small and uncontrolled to establish a survival benefit. PMDA noted that open-label assessment, rehabilitation, motivation and other care can affect some endpoints.

PMDA RiHEART review report

Medical documents used to compare regenerative medicine study results and follow-up in Japan

Chronic motor paralysis after traumatic brain injury

Akuugo · modified allogeneic (donor-derived) bone-marrow MSCs · stereotactic brain implantation

46 treated vs 15 sham · randomized · 24 weeks

Published result

Mean FMMS change was +8.3 in the pooled treated group versus +2.3 after sham surgery. The between-group difference was +6.0 points (95% CI 0.3 to 11.8; P=0.0401).

What it does not prove

PMDA noted uncertainty about how much the motor-score change translates into daily-life improvement. The indication is traumatic brain injury with stable chronic motor deficits, not post-stroke paralysis.

PMDA Akuugo review report

Selected knee osteoarthritis with cartilage defect

JACC · autologous (patient’s own) cultured cartilage · two-surgery transplantation route

26 JACC vs 27 efficacy-control patients · open-label · 52 weeks

Published result

Adjusted between-group difference in WOMAC change at Week 52 was -11.69 points (95% CI -17.63 to -5.75; P=0.0002). Lower WOMAC scores mean fewer knee symptoms in this study.

What it does not prove

The study was open-label and used a patient-reported endpoint. JACC is cultured cartilage, not a generic stem-cell injection. The reviewed knee indication requires a cartilage defect of at least 2 cm² and inadequate response to conservative care.

PMDA JACC review report

Approval status also needs a date check. PMDA lists Akuugo as conditionally/time-limited approved in July 2024, AMCHEPRY and RiHEART as approved in March 2026, and JACC’s knee indication as a May 2025 partial-change approval. Stemirac’s original December 2018 approval was conditional/time-limited; a full-approval application was announced in November 2025, but an application is not the same as a new approval. Confirm current authorization and availability before travel.

What the study scores mean

These scales are useful because they let patients compare the same function before and after treatment. They are not interchangeable across diseases.

AIS

Spinal-cord neurologic grade. A higher grade generally means less severe impairment.

SCIM-III

Independence in daily activities after spinal cord injury. Higher means more independence.

MDS-UPDRS Part III

Clinician-rated Parkinson motor examination. Lower scores mean fewer motor signs.

FMMS

Fugl-Meyer motor score for movement after brain injury. Higher means better motor function.

NYHA I-IV

Heart-failure symptom class. A lower class means less activity limitation.

6MWD

Distance walked in six minutes. It is a practical measure of exercise capacity.

Peak VO2

Oxygen use during exercise testing. It reflects cardiopulmonary exercise capacity.

WOMAC

Knee pain, stiffness and function score. In the JACC study, lower was better.

Conditions people keep searching for

What the current status means for common patient questions

The current PMDA review list does not show a general stem-cell approval for most chronic conditions advertised online. A private provision plan may still exist, but its legal route and evidence should be checked separately.

Chronic stroke

Do not confuse stroke with the Akuugo TBI indication

Akuugo is for chronic motor paralysis associated with traumatic brain injury. It is not a PMDA approval for post-stroke paralysis. For a stroke-related private cell program, ask for the exact provision plan, route, evidence and outcome measures. Read the cardiovascular and cerebrovascular guide.

Diabetes

No general PMDA-approved stem-cell indication on the current list

Type 1 and type 2 diabetes are different problems. If a private cell program is proposed, useful review points include diabetes type, insulin use, HbA1c, C-peptide when available, complications and the specific clinical evidence behind the protocol. Read the diabetes guide.

Liver and kidney dysfunction

Organ function should be measured, not described with vague wellness claims

There is no general PMDA stem-cell product indication for chronic liver or kidney dysfunction on the current review list. A useful discussion should focus on diagnosis, stage, eGFR or liver function, complications, current specialist care and the protocol’s human evidence.

Knee osteoarthritis

There is a defined cartilage product route, but it is not the same as an MSC injection

JACC has a PMDA-reviewed indication for selected knee osteoarthritis with a cartilage defect of at least 2 cm² after insufficient response to conservative care. Private intra-articular MSC programs require their own evidence and plan review. Read the knee joint guide.

Anti-aging, ovarian, ED and chronic pain

Treat these as separate private or investigational questions

These are not general PMDA-approved stem-cell product indications on the current review list. Ask what is being measured, how long patients are followed, what evidence comes from comparable patients and what happens if the planned cell processing or administration cannot proceed.

Blood cancers and transplant medicine

Hematopoietic stem-cell transplantation is a different treatment field

Stem-cell transplantation for blood diseases is established specialist care and is not the same as private regenerative MSC therapy. Survival depends on the exact cancer or blood disorder, disease status, donor and transplant factors, so a single “stem cell survival rate” is not medically meaningful.

Not sure which route matches what you have found?

Send the basic information you already have. We can help you organize the questions and identify what is still missing before you spend more time comparing options.

Help Me Sort Through the OptionsWhatsApp I’ll Send What I HaveLINE

What actually decides who’s eligible

Your diagnosis alone is usually not enough

Timing, disease subtype, current function, previous treatment and procedure risk can change whether a specific Japanese pathway is relevant. These are the records that make a first review more useful.

Spinal cord injury or TBI

Injury date and cause, lesion level or location, AIS or GOS-E if known, current motor and sensory function, MRI reports, surgery history and rehabilitation progress.

Parkinson disease

Diagnosis duration, current levodopa and other medication schedule, ON and OFF symptoms, MDS-UPDRS or H&Y stage if available, dyskinesia history and recent brain imaging reports.

Heart failure

Cause of heart failure, latest LVEF, NYHA class, six-minute walk or exercise testing if available, coronary procedures, CRT or device history, medication list and major surgical risks.

Knee osteoarthritis

Weight-bearing X-ray or MRI report, cartilage defect information, previous exercise therapy, injections or surgery, pain and walking limits, and whether joint replacement has been discussed.

Diabetes or organ dysfunction

Exact diagnosis and stage, recent HbA1c and insulin information for diabetes, kidney or liver function results, current specialist plan, complications and the outcome you want measured.

Safety can also change whether you’re eligible.Active infection, unstable heart or lung disease, current or recent cancer in some protocols, immune status, anticoagulation, anesthesia risk, pregnancy and other factors may affect whether a procedure can proceed. The exact exclusions are product- and protocol-specific.

Results you can actually measure

Ask what will be measured after the procedure

A useful plan defines baseline measurements and follow-up dates before treatment starts. “Feeling better” alone is not enough to judge whether a costly intervention changed the disease or function.

Neurologic function

Spinal cord injury, TBI and Parkinson disease

Examples include AIS and SCIM for spinal cord injury, FMMS or other motor scales for TBI, and MDS-UPDRS plus H&Y stage for Parkinson disease. Function should be compared with the patient’s own baseline.

Cardiac function

Heart failure and exercise capacity

Useful measures include NYHA class, six-minute walk distance, peak VO2, LVEF, ventricular volumes, symptoms and heart-failure hospitalization. One favorable measure should not be used to hide worsening in another.

Joint function

Pain, walking and activity

Track a reproducible pain and function score, walking or stair limits, rescue medication, rehabilitation progress and imaging only when the protocol has a clear reason to use it.

Metabolic and organ function

Use disease-specific laboratory outcomes

For diabetes, HbA1c, insulin need and C-peptide where appropriate are more useful than general wellness scores. Kidney and liver programs should use established organ-function measures and specialist follow-up.

There is no single stem-cell survival rate

For spinal cord injury, Parkinson disease and knee disease, survival is not the main efficacy endpoint. RiHEART was reviewed using an 8-patient exploratory study, which is too small to prove a survival benefit. For cancer and hematopoietic stem-cell transplantation, survival should be discussed using the exact cancer, disease status and transplant setting rather than a general regenerative medicine percentage.

220 daysStemirac spinal-cord efficacy assessment.

24 weeksAkuugo primary TBI motor endpoint; follow-up also continued to Week 48.

52 weeksRiHEART cardiac and exercise assessment.

52 weeksJACC knee WOMAC primary endpoint.

24 monthsAMCHEPRY Parkinson motor follow-up.

These are study assessment windows, not promised recovery times. Rehabilitation, disease progression, surgery and other care can affect the result.

Want a clearer checklist before you spend?

We can help you organize the records, questions, cost points and follow-up items that should be clear before you make a decision.

Talk Before I DecideWhatsApp Help Me Build My ChecklistLINE

What you’ll actually pay

There is no single price for stem cell care in Japan

A private cultured-cell infusion, a cartilage transplantation, a stereotactic brain procedure and an iPS-cell cardiac surgery are not comparable products. Ask for a written estimate tied to the exact route.

¥2.2MOne MHLW-public self-pay plan lists ¥2,200,000 including tax per treatment. This is a single program example, not a Japan-wide price. The document also says the fee may vary with patient circumstances.

30 daysThe same plan asks patients to return once every 30 days through 6 months after treatment. This is its own follow-up schedule, not a national rule.

Review and testingSpecialist assessment, laboratory tests and imaging requested before a decision.

Cell collection and processingHarvest, culture, quality checks, storage or transport when applicable.

Administration or surgeryInfusion, local injection, transplantation, anesthesia or inpatient care depending on route.

MedicinesSupportive treatment, immunosuppression or other medication required by the protocol.

Follow-up and rehabilitationRepeat testing, rehabilitation, outcome measurement and complication management.

Travel and communicationTranslation, scheduling, local travel and additional stays if the medical plan requires them.

The same public consent document states that costs already incurred after cell collection or processing may remain payable after consent is withdrawn. Before paying, ask for a written total covering assessment, harvest and processing, procedure or surgery, medicines, follow-up, rehabilitation, cancellation and travel-related costs. MHLW public provision-plan example

Safety: it depends on the procedure

The risks are not the same for an infusion, joint procedure, brain implant and heart surgery

The consent discussion should match the actual procedure and cell product. Ask who manages complications in Japan and what follow-up is available after you return home.

Stemirac study

0 serious AEs / deaths

In Study STR01-03, PMDA reported no deaths or serious adverse events. Two patients had Grade 2 anemia related to peripheral-blood collection and one had Grade 1 puncture-site pain related to bone-marrow collection. N=13 after treatment, so this is limited safety experience.

JACC knee study

20/26 site pain

During the treatment period, application-site pain occurred in 20/26 (76.9%) and limb venous thrombosis in 5/26 (19.2%). PMDA reported no serious adverse events or deaths in the study. The thromboses were detected after surgery and were asymptomatic in the five cases described in the review.

RiHEART study

5/8 serious AEs

Study CVSC0005 reported serious adverse events in 5/8 patients; the review ruled out a causal relationship to RiHEART for those events. Events for which a relationship to the 90-day immunosuppressant regimen could not be ruled out occurred in 7/8. The route also requires thoracotomy.

Self-pay IV MSC example

Causality unknown

One MHLW-public consent document for IV adipose-derived MSCs warns that fatal pulmonary embolism has been reported after this type of infusion, while stating that the causal relationship was unknown. A consent discussion should explain route-specific risks rather than calling cell therapy generally “safe.”

These are study- or plan-specific observations, not personal risk estimates. Risk changes with the product, cell source, dose, administration route, surgery, medicines, disease and patient health.

Support for patients coming from overseas

What we do before you make a commitment

We organize your records, prepare the questions that still need an answer, support Japan-side appointment requests and translate medical information. We do not diagnose, prescribe or promise eligibility or results.

How the coordination works

Build a clean medical timeline

Organize diagnosis, onset or injury date, major procedures, current medicines, recent reports, imaging and laboratory results.

Identify the missing questions

Prepare clear questions on regulatory status, evidence, procedure, patient selection, expected measurement, risks, recovery, cost and cancellation terms.

Support appointment requests and translation

Help prepare the information needed for Japan-side appointment coordination and support communication around records and written instructions.

Clarify what happens before and after travel

Organize the expected schedule, documents, estimated cost items, follow-up requirements and the information you should keep for your home medical team.

Medical records prepared for appointment coordination and translation support in Japan

Six facts to have in writing before you pay

Keep these six points in the written information you receive. They make it easier to compare options, understand what is included, and know what still needs clarification.

Exact product or cell source: autologous or allogeneic, tissue source and whether cells are cultured or modified.

Administration route and dose: IV infusion, local injection, stereotactic implant, sheet transplant or another method.

Regulatory route: PMDA product approval, research registration or ASRM provision-plan identifier.

Comparable human evidence: patient number, control group, endpoint, follow-up and adverse-event denominator.

Full cost and cancellation terms: what is included and what remains payable if processing or treatment cannot proceed.

Aftercare: follow-up dates, rehabilitation, complication contact, what information your home medical team receives, and whether repeat treatment is ever planned.

Related patient information

Questions worth answering before travel

Short answers for patients comparing Japan

Use official product information and the exact provision plan when possible. A general sales description cannot replace the details that apply to your diagnosis.

Does a provision plan mean PMDA approval?

No. A provision plan under Japan’s Act on the Safety of Regenerative Medicine is a separate legal route. PMDA marketing approval applies to a defined product, indication and method of use.

Does Stemirac’s 12/13 result mean I have a 92.3% chance of improving?

No. It means 12 of 13 efficacy-evaluable patients in a small uncontrolled exploratory study improved by at least one AIS grade by the study assessment. It is not an individual probability and does not remove the effects of natural recovery, rehabilitation or patient selection.

What makes one study result more useful than another?

Look for the patient number, a relevant comparison group, a predefined endpoint, follow-up long enough for the disease, and adverse-event counts with a denominator. A percentage without these details is hard to interpret.

Can chronic stroke use the Akuugo result?

Do not assume so. Akuugo’s reviewed indication is chronic motor paralysis after traumatic brain injury. Post-stroke paralysis is a different condition and requires its own regulatory route and evidence.

How much should I budget?

There is no single Japan-wide self-pay price. One MHLW-public provision-plan document lists ¥2.2 million including tax per treatment for one specific autologous adipose-derived MSC program. Use it only as a documented example, not a price quote for another disease or procedure.

What should I send first?

Send your exact diagnosis, age, onset or injury date, major procedures, current medicines, latest specialist report, relevant imaging report and recent laboratory results. For neurologic or heart conditions, include any formal function score you already have.

What should make me ask for more detail?

Ask for clarification if the same cell infusion is promoted for many unrelated diseases, improvement is guaranteed, no product or provision-plan identifier is given, percentages have no patient number or follow-up time, or price is quoted before the actual protocol and aftercare are clear.

PMDA regenerative medical product review reports PMDA optimal-use guidelines MHLW amended ASRM framework MHLW e-Regenerative Medicine portal PMDA Stemirac review Stemirac full-approval application notice PMDA AMCHEPRY review PMDA RiHEART review PMDA Akuugo review PMDA JACC review MHLW public provision-plan cost example

Medical information reviewed against official sources available on August 11, 2026. Regulatory status, indications, availability and fees can change. This information is educational and does not replace diagnosis, physician advice, informed consent or emergency care.

Start with what you’ve already got

Get the facts organized before you make a decision

Send your diagnosis, age, onset or injury date, latest report or imaging summary, current medicines and what you most want clarified. We’ll help organize the information for appointment coordination and medical translation, and spot the questions that still need a clear answer.

Help Me Work Out the Next StepWhatsApp +81-8070161366 Send What I HaveLINE +81-8075357788

International support is limited to information collection, appointment coordination and medical translation. Eligibility, diagnosis, treatment decisions, risks and expected outcomes must be determined by qualified medical professionals. We don’t guarantee results or eligibility for any specific pathway.